Drug intelligence / Profile preview

A2342

Development stage: Unknown
Lead developer: Ipsen
Modality: Small Molecules
Administration: Oral

Overview

**A2342** is an oral, systemic inhibitor of the sodium-taurocholate co-transporting peptide (NTCP), a hepatic transporter crucial for bile acid uptake and a key entry point for hepatitis B and D viruses. It is being evaluated in early clinical trials for the treatment of viral and cholestatic diseases, particularly in the context of rare liver disorders and hepatitis infections.

Other names: 8501022

Targets

NTCP (Na+-taurocholate cotransporting polypeptide)

Beyond the preview

Go deeper on A2342.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on A2342.

Explore the full profile